Ironwood Pharmaceuticals Inc expected to post earnings of 15 cents a share - Earnings Preview

Ironwood Pharmaceuticals

06/08/2024 19:35

* Ironwood Pharmaceuticals Inc  IRWD.OQ   IRWD.O  is
expected
to show a fall in quarterly revenue when it reports  results on
August 8 for the period ending June 30 2024
    * The Boston Massachusetts-based  company is expected to
report a
0.4% decrease in revenue to $106.996 million from $107.38
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Ironwood Pharmaceuticals
Inc
is for earnings of 15 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ironwood
Pharmaceuticals Inc is $14.00​, above​ its last closing price
of $6.20. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  0.15        0.19       -0.02     Missed  -110.5
 Dec. 31 2024  0.21        0.21       -0.01     Missed  -104.9
 Sep. 30 2023  0.17        0.16       0.09      Missed  -42.9​
 Jun. 30 2023  0.26        0.25       0.31      Beat    25.7
 ​​Mar.        0.23        0.24       0.25      Beat    3.1
 31 2023                                                
 Jan. 1 0001   0.26        0.27       0.27      Met     0​
 Sep. 30 2022  0.26        0.27       0.28      Beat    5.7
 Jun. 30 2022  0.30        0.30       0.21      Missed  -28.8
 This summary was machine generated August 6 at 18:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)